The global anti-fungal therapy market valuation was US$ 13.8 billion in 2022 and is expected to expand at a CAGR of 4.7% from 2023 to 2033. The market is projected to reach US$ 22.8 billion by 2033. The azoles segment is leading the market by drug class with a share of about 29.1% in 2022.
| Data Points | Market Insights |
|---|---|
| Anti-fungal Therapy Market Size, 2022 | US$ 13.8 Billion |
| Anti-fungal Therapy Market Value, 2023 | US$ 14.4 Billion |
| Anticipated Market Value, 2033 | US$ 22.8 Billion |
| Value-based CAGR (2023 to 2033) | 4.7% |
| Market Share of Top 5 Countries | 52.3% |
| Key Market Players | Eli Lilly and Company, Sanofi S.A, Abbott Laboratories, Arcadia Consumer Healthcare Inc., Astellas Pharma Inc, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis A.G, Gilead Sciences Inc., Johnson & Johnson’s, MerzPharma, Enzon Pharmaceuticals Inc., Glenmark, Dr. Reddy's Laboratories, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Apotex Inc., Zydus Cadila, Aurobindo Pharma, Cipla Inc., Dr. Reddy's Laboratories Ltd., Pfizer Inc., Torrent Pharmaceuticals Ltd., Bayer AG. |
Rapid initiation of antifungal therapy is essential in the management of fungal diseases that target either the plasma membrane or the cell wall. Increasing perception rates of primary classes of antifungal agents act as a driver for the growth of the antifungal drugs and therapies market.
The efforts of government and private organizations to raise awareness about various fungal illnesses are projected to boost the anti-fungal drugs market. Furthermore, an increase in fungal infection cases such as aspergillosis and candidiasis is one of the major reasons driving the growth of the anti-microbial/anti-fungal test market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market share for anti-fungal therapies was around 30.8% of the overall global antibiotics market, which was worth US$ 42.5 billion in 2022. The market grew at a CAGR of 3.0% during the historical period.
| Historical CAGR (2017 to 2022) | 3.0% |
|---|
The demand for anti-fungal therapies expanded at a CAGR of 4.7% from 2023 to 2033, owing to the rising cases of fungal diseases like candidiasis, aspergillosis and onychomycosis.Anti-fungal therapies are widely employed in the mycosis control and treatment/mycosis management market.
People are looking for products that would promote faster recovery and prevention of fungal diseases. Over the forecast period, the market is projected to be driven by the pharmaceutical industries’ formulations and the ongoing developments in the discovery of novel treatments for fungal diseases.
For instance, on 7 June 2022, the USA Food and Drug Administration (FDA) approved the use of Sanofi Dupixent (dupilumab) for children who are six months to 5 years old with moderate-to-severe atopic dermatitis.
Furthermore, the market for anti-fungal therapies is growing due to rising new drug development and clinical trials activities. For instance, three novel antifungals are undergoing phase II and phase III clinical studies, namely rezafungin, olorofim, and fosmanogepix by Amplyx Pharmaceuticals, which were acquired by Pfizer in April 2022.
The market is anticipated to grow as a result of an increase in initiatives by private and public organizations to spread awareness about a variety of fungal illnesses. For instance, CDC (Centres For Disease Control And Prevention) and its partners organized Fungal Disease Awareness Week, September 20-24, 2022. The purpose of this program is to highlight the importance of detecting and diagnosing serious fungal diseases early in patients to provide life-saving treatment.
Fungal infections of the eyes, mouth, and skin, including superficial and systematic infections, are projected to fuel market expansion. The availability and effective adoption of generic antifungal drugs like miconazole, clotrimazole, and econazole for the treatment of fungal infections create significant opportunities in the market. Anti-fungal therapies that doctors strongly prescribe for patients to treat fungal infections are also considered one of the key factors in boosting the market.
Principal Consultant
Sometimes, antifungal therapy is harmful to the patient and causes side effects such as heart arrhythmia, oliguria, promethazine and muscle spasms or pain. For instance, according to the National Library of Medicine, amphotericin B deoxycholate therapy is known to cause side effects like chills, the risk of hypotension, migraines, hypomagnesemia, renal insufficiency, emesis, rigors, and pyrexia.
The market is expected to be hampered by strict government regulations, patent expirations, an increase in fungal resistance to drugs, etc., during the projected period. Furthermore, it is anticipated that rising drug recall rates may hamper the market's expansion. These factors cumulatively propose a negative effect on the growth of the anti-fungal therapy market.
| Country | CAGR (2023 to 2033) |
|---|---|
| United States | 4.8% |
| India | 4.2% |
| China | 4.4% |
| Germany | 3.8% |
| United Kingdom | 3.9% |
The United States anti-fungal therapy market is expected to grow at a CAGR of 4.8% over the forecast period.
A major driver of the market expansion for anti-fungal therapies in the United States is the rising prevalence of fungal infections among people. For instance, according to Oxford University Press, 666,235 cases of fungal infections were identified in the United States. Infections with pneumocystis, candida, and aspergillus accounted for 76.3% of reported fungal infections and 81.1% of related treatment costs.
Key players in the United States engage in non-organic actions, such as mergers and acquisitions, to expand their antifungal therapy drug portfolio. This is a key element driving the demand for antifungal medications in the USA
Germany held around 32.9% share of the European market in 2022, due to the prevalence of allergic fungal diseases like aspergillosis and dermatophytosis. The market in Germany is expected to grow at a CAGR of 3.8% through 2033.
Fungal infections are considered a significant public health issue in Germany. Germany will see profitable growth as more and more pharmaceutical drugs are manufactured for various fungal diseases. For instance, in 2018, Pfizer started new manufacturing units for anti-fungal medicines in Germany.
In addition, the provision of public health advocacy for people with fungal diseases is another area where the government and other private groups are investing heavily, and it is anticipated to drive the market for anti-fungal therapies in Germany.
The market in India is set to exhibit a CAGR of 4.2% over the forecast period.
In India, strong financing and the launch of several healthcare programs like Pradhan Mantri Jan Arogya Yojana and Ayushman Bharat offer free healthcare facilities and reimbursement options to patients receiving healthcare treatment. This is boosting the demand for anti-fungal therapy market.
Increasing disposable incomes of middle-class families enable them to spend more money on their healthcare expenditure to get high-quality treatment facilities. The market is expected to grow more quickly throughout the forecast period due to increased expenditure on continued research and development for anti-fungal drug innovations. Increasing awareness of fungal infection and the adoption of antifungal drugs are driving the anti-fungal therapy market.
The market in the United Kingdom is expected to rise at a CAGR of 3.9% through 2033.
In the United Kingdom, accessibility of antifungal drugs and rising awareness among healthcare professionals are expected to drive the market in the United Kingdom. The United Kingdom has a well-established healthcare system, and antifungal therapies are prescribed to patients only by healthcare professionals.
The market in China is expected to rise at a CAGR of 4.4% through 2033. Rapid urbanization, evolving lifestyle, and increasing healthcare awareness boost sales of antifungal drugs in China. Also, the healthcare system in China has been evolving, and access to healthcare services has improved in recent years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Top Drug Class | Azoles |
|---|---|
| Market Share | 29.1% |
Azoles constitute a share of 29.1% of the anti-fungal therapy industry share by drug class. The increasing cases of fungal diseases like blastomycosis, histoplasmosis, and ringworm are contributing to market expansion. Azoles prevent the formation of fungus sterols. Azole antifungal agents help in the treatment of systemic fungal infections, contributing to market expansion.
| Top Indication | Candidiasis |
|---|---|
| Market Share | 35.0% |
The candidiasis segment holds a share of 35.0% of the market by indication. The most common fungal infection is candidiasis, which is caused by yeast. The rising cases of candidiasis are driving the anti-fungal therapy market.
| Top Route of Administration | Topical |
|---|---|
| Market Share | 53.7% |
The topical route of administration of drugs is more preferred by patients compared to oral and parenteral. The topical segment holds a prominent market share of 53.7%, rising at a CAGR of 4.7% over the forecast period. Topical formulation is less expensive than oral formulation and has fewer adverse side effects. Also, the topical route of administration has a higher retention rate and direct access, further propelling the demand for anti-fungal therapies.
| Top Distribution Channel | Retail Pharmacies |
|---|---|
| Market Share | 44.0% |
Retail pharmacies hold a prominent share of 44.0% of the market by distribution channels. The growing prevalence of antifungal infections like dermatophytosis, aspergillus, and superficial mycoses and the developments in drug discovery have driven this segment’s growth, propelling the anti-fungal therapy market.
The market for the production of anti-fungal therapies/drugs is fragmented due to the presence of several key players. These businesses are employing strategies including collaborations, partnerships, mergers and acquisitions, and new product launches to satisfy consumer demand and increase their client base. Also, governments are focusing on taking initiatives to invest in mobility equipment and enhance the anti-fungal drug and therapy market dynamics.
Recent Developments in the Anti-fungal Therapy Market
Similarly, more recent developments related to anti-fungal therapies/drugs have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Billion for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, Israel, South Africa and North Africa |
| Key Market Segments Covered | Drug Class, Indication, Route of Administration, Distribution Channel and Region |
| Key Companies Profiled | Eli Lilly and Company, Sanofi S.A, Abbott Laboratories, Arcadia Consumer Healthcare Inc., Astellas Pharma Inc, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis A.G, Gilead Sciences Inc., Johnson & Johnson’s, MerzPharma, Enzon Pharmaceuticals Inc., Glenmark, Dr. Reddy's Laboratories, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Apotex Inc., Zydus Cadila, Aurobindo Pharma, Cipla Inc., Dr. Reddy's Laboratories Ltd., Pfizer Inc., Torrent Pharmaceuticals Ltd., Bayer AG |
| Pricing | Available upon Request |
The global anti-fungal therapy market was worth US$ 13.8 billion in 2022 and is set to grow at a CAGR of 4.7% over the next ten years.
Rising prevalence of fungal infections such as candidiasis and adoption of anti-fungal therapies.
The United States, India, China, Germany, and the United Kingdom are expected to drive demand for anti-fungal therapies.
The market is expected to reach US$ 22.8 billion by 2033, with sales revenue expected to register a 4.7% CAGR over the forecast period.
Demand for anti-fungal therapies in Europe is expected to register a growth rate of 4.2% through 2033.
The market in India is projected to grow at a CAGR of 4.2% over the forecast period.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Development/Innovation Trends
4. Key Success Factors
4.1. Disease Dermatology, By Region
4.2. Pipeline Assessment
4.3. Value chain Analysis
4.4. Key Promotional Strategies, By Key Manufacturers
4.5. Regulatory Landscape
4.6. PESTLE Analysis
4.7. PORTER’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure
5.1.3. Global Antibiotics Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Key Player’s Historic Growth
5.2.2. Market Consolidation Activities
5.2.3. Rising Prevalence of Fungal Infection
5.2.4. Formulation and Development
5.2.5. Effect of Antifungal therapies
5.2.6. Growing Preference of Antifungal Therapies
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand Value or Size in (US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
6.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2017 to 2022
7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
7.3.1. Azoles
7.3.2. Polyene macrolides
7.3.3. Echinocandins
7.3.4. Allylamines
7.3.5. Others
7.4. Market Attractiveness Analysis By Drug Class
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) By Indication, 2017 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
8.3.1. Dermatophytosis
8.3.2. Aspergillosis
8.3.3. Candidiasis
8.3.4. Others
8.4. Market Attractiveness Analysis By Indication
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2017 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
9.3.1. Oral
9.3.2. Topical
9.3.3. Parentral
9.4. Market Attractiveness Analysis By Route of Administration
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) By Distribution Channel, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
10.3.1. Retail Pharmacies
10.3.2. Hospital Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
11.1. Introduction
11.2. Historical Market Size (US$ Million) Analysis by Region, 2017 to 2022
11.3. Current Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. East Asia
11.3.5. South Asia
11.3.6. Oceania
11.3.7. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
12.1. Introduction
12.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
12.3.1. By Country
12.3.1.1. USA
12.3.1.2. Canada
12.3.2. By Drug Class
12.3.3. By Indication
12.3.4. By Route of Administration
12.3.5. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Drug Class
12.4.3. By Indication
12.4.4. By Distribution Channel
12.5. Market Trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country Level Analysis & Forecast
12.8.1. USA Market Analysis
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Drug Class
12.8.1.2.2. By Indication
12.8.1.2.3. By Route of Administration
12.8.1.2.4. By Distribution Channel
12.8.2. Canada Market Analysis
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Drug Class
12.8.2.2.2. By Indication
12.8.2.2.3. By Route of Administration
12.8.2.2.4. By Distribution Channel
13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. Mexico
13.3.1.2. Brazil
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Drug Class
13.3.3. By Indication
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug Class
13.4.3. By Indication
13.4.4. By Route of Administration
13.4.5. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. Mexico Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Drug Class
13.8.1.2.2. By Indication
13.8.1.2.3. By Route of Administration
13.8.1.2.4. By Distribution Channel
13.8.2. Brazil Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Drug Class
13.8.2.2.2. By Indication
13.8.2.2.3. By Route of Administration
13.8.2.2.4. By Distribution Channel
13.8.3. Argentina Market Analysis
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Drug Class
13.8.3.2.2. By Indication
13.8.3.2.3. By Route of Administration
13.8.3.2.4. By Distribution Channel
14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. UK
14.3.1.5. Spain
14.3.1.6. BENELUX
14.3.1.7. Russia
14.3.1.8. Rest of Europe
14.3.2. By Drug Class
14.3.3. By Indication
14.3.4. By Route of Administration
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug Class
14.4.3. By Indication
14.4.4. By Route of Administration
14.4.5. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Germany Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Drug Class
14.8.1.2.2. By Indication
14.8.1.2.3. By Route of Administration
14.8.1.2.4. By Distribution Channel
14.8.2. Italy Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Drug Class
14.8.2.2.2. By Indication
14.8.2.2.3. By Route of Administration
14.8.2.2.4. By Distribution Channel
14.8.3. France Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Drug Class
14.8.3.2.2. By Indication
14.8.3.2.3. By Route of Administration
14.8.3.2.4. By Distribution Channel
14.8.4. UK Market Analysis
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Drug Class
14.8.4.2.2. By Indication
14.8.4.2.3. By Route of Administration
14.8.4.2.4. By Distribution Channel
14.8.5. Spain Market Analysis
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast by Market Taxonomy
14.8.5.2.1. By Drug Class
14.8.5.2.2. By Indication
14.8.5.2.3. By Route of Administration
14.8.5.2.4. By Distribution Channel
14.8.6. BENELUX Market Analysis
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast by Market Taxonomy
14.8.6.2.1. By Drug Class
14.8.6.2.2. By Indication
14.8.6.2.3. By Route of Administration
14.8.6.2.4. By Distribution Channel
14.8.7. Russia Market Analysis
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast by Market Taxonomy
14.8.7.2.1. By Drug Class
14.8.7.2.2. By Indication
14.8.7.2.3. By Route of Administration
14.8.7.2.4. By Distribution Channel
15. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Drug Class
15.3.3. By Indication
15.3.4. By Route of Administration
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Class
15.4.3. By Indication
15.4.4. By Route of Administration
15.4.5. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. China Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Drug Class
15.8.1.2.2. By Indication
15.8.1.2.3. By Route of Administration
15.8.1.2.4. By Distribution Channel
15.8.2. Japan Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Drug Class
15.8.2.2.2. By Indication
15.8.2.2.3. By Route of Administration
15.8.2.2.4. By Distribution Channel
15.8.3. South Korea Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Drug Class
15.8.3.2.2. By Indication
15.8.3.2.3. By Route of Administration
15.8.3.2.4. By Distribution Channel
16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Malaysia
16.3.1.4. Thailand
16.3.1.5. Rest of South Asia
16.3.2. By Drug Class
16.3.3. By Indication
16.3.4. By Route of Administration
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Class
16.4.3. By Indication
16.4.4. By Route of Administration
16.4.5. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. India Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Drug Class
16.8.1.2.2. By Indication
16.8.1.2.3. By Route of Administration
16.8.1.2.4. By Distribution Channel
16.8.2. Indonesia Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Drug Class
16.8.2.2.2. By Indication
16.8.2.2.3. By Route of Administration
16.8.2.2.4. By Distribution Channel
16.8.3. Malaysia Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Drug Class
16.8.3.2.2. By Indication
16.8.3.2.3. By Route of Administration
16.8.3.2.4. By Distribution Channel
16.8.4. Thailand Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Drug Class
16.8.4.2.2. By Indication
16.8.4.2.3. By Route of Administration
16.8.4.2.4. By Distribution Channel
17. Oceania Market 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Drug Class
17.3.3. By Indication
17.3.4. By Route of Administration
17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Class
17.4.3. By Indication
17.4.4. By Route of Administration
17.4.5. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. Australia Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Drug Class
17.8.1.2.2. By Indication
17.8.1.2.3. By Route of Administration
17.8.1.2.4. By Distribution Channel
17.8.2. New Zealand Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Drug Class
17.8.2.2.2. By Indication
17.8.2.2.3. By Route of Administration
17.8.2.2.4. By Distribution Channel
18. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. GCC Countries
18.3.1.2. Türkiye
18.3.1.3. South Africa
18.3.1.4. Rest of Middle East and Africa
18.3.2. By Drug Class
18.3.3. By Indication
18.3.4. By Route of Administration
18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug Class
18.4.3. By Indication
18.4.4. By Route of Administration
18.4.5. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. GCC Countries Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Drug Class
18.8.1.2.2. By Indication
18.8.1.2.3. By Route of Administration
18.8.1.2.4. By Distribution Channel
18.8.2. Türkiye Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Drug Class
18.8.2.2.2. By Indication
18.8.2.2.3. By Route of Administration
18.8.2.2.4. By Distribution Channel
18.8.3. South Africa Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Drug Class
18.8.3.2.2. By Indication
18.8.3.2.3. By Route of Administration
18.8.3.2.4. By Distribution Channel
18.8.4. North Africa Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Drug Class
18.8.4.2.2. By Indication
18.8.4.2.3. By Route of Administration
18.8.4.2.4. By Distribution Channel
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players (%)
19.3. Market Presence Analysis
19.3.1. By Regional Footprint of Players
19.3.2. Drug Class Footprint of Players
19.3.3. Channel Footprint of Players
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Competition Deep Dive
20.3.1. Eli Lilly and Company.
20.3.1.1. Overview
20.3.1.2. Product & Services Portfolio
20.3.1.3. Key Financials
20.3.1.4. SWOT Analysis
20.3.1.5. Key Developments
20.3.1.6. Sales Footprint
20.3.1.7. Strategy Overview
20.3.1.7.1. Marketing Strategy
20.3.1.7.2. Product Strategy
20.3.1.7.3. Channel Strategy
20.3.2. Sanofi S.A
20.3.2.1. Overview
20.3.2.2. Product & Services Portfolio
20.3.2.3. Key Financials
20.3.2.4. SWOT Analysis
20.3.2.5. Key Developments
20.3.2.6. Sales Footprint
20.3.2.7. Strategy Overview
20.3.2.7.1. Marketing Strategy
20.3.2.7.2. Product Strategy
20.3.2.7.3. Channel Strategy
20.3.3. Abbott Laboratories
20.3.3.1. Overview
20.3.3.2. Product & Services Portfolio
20.3.3.3. Key Financials
20.3.3.4. SWOT Analysis
20.3.3.5. Key Developments
20.3.3.6. Sales Footprint
20.3.3.7. Strategy Overview
20.3.3.7.1. Marketing Strategy
20.3.3.7.2. Product Strategy
20.3.3.7.3. Channel Strategy
20.3.4. Arcadia Consumer Healthcare Inc.
20.3.4.1. Overview
20.3.4.2. Product & Services Portfolio
20.3.4.3. Key Financials
20.3.4.4. SWOT Analysis
20.3.4.5. Key Developments
20.3.4.6. Sales Footprint
20.3.4.7. Strategy Overview
20.3.4.7.1. Marketing Strategy
20.3.4.7.2. Product Strategy
20.3.4.7.3. Channel Strategy
20.3.5. Astellas Pharma Inc
20.3.5.1. Overview
20.3.5.2. Product & Services Portfolio
20.3.5.3. Key Financials
20.3.5.4. SWOT Analysis
20.3.5.5. Key Developments
20.3.5.6. Sales Footprint
20.3.5.7. Strategy Overview
20.3.5.7.1. Marketing Strategy
20.3.5.7.2. Product Strategy
20.3.5.7.3. Channel Strategy
20.3.6. GlaxoSmithKline Plc
20.3.6.1. Overview
20.3.6.2. Product & Services Portfolio
20.3.6.3. Key Financials
20.3.6.4. SWOT Analysis
20.3.6.5. Key Developments
20.3.6.6. Sales Footprint
20.3.6.7. Strategy Overview
20.3.6.7.1. Marketing Strategy
20.3.6.7.2. Product Strategy
20.3.6.7.3. Channel Strategy
20.3.7. Merck & Co. Inc.
20.3.7.1. Overview
20.3.7.2. Product & Services Portfolio
20.3.7.3. Key Financials
20.3.7.4. SWOT Analysis
20.3.7.5. Key Developments
20.3.7.6. Sales Footprint
20.3.7.7. Strategy Overview
20.3.7.7.1. Marketing Strategy
20.3.7.7.2. Product Strategy
20.3.7.7.3. Channel Strategy
20.3.8. Novartis A.G.
20.3.8.1. Overview
20.3.8.2. Product & Services Portfolio
20.3.8.3. Key Financials
20.3.8.4. SWOT Analysis
20.3.8.5. Key Developments
20.3.8.6. Sales Footprint
20.3.8.7. Strategy Overview
20.3.8.7.1. Marketing Strategy
20.3.8.7.2. Product Strategy
20.3.8.7.3. Channel Strategy
20.3.9. Gilead Sciences Inc.
20.3.9.1. Overview
20.3.9.2. Product & Services Portfolio
20.3.9.3. Key Financials
20.3.9.4. SWOT Analysis
20.3.9.5. Key Developments
20.3.9.6. Sales Footprint
20.3.9.7. Strategy Overview
20.3.9.7.1. Marketing Strategy
20.3.9.7.2. Product Strategy
20.3.9.7.3. Channel Strategy
20.3.10. Johnson & Johnson’s
20.3.10.1. Overview
20.3.10.2. Product & Services Portfolio
20.3.10.3. Key Financials
20.3.10.4. SWOT Analysis
20.3.10.5. Key Developments
20.3.10.6. Sales Footprint
20.3.10.7. Strategy Overview
20.3.10.7.1. Marketing Strategy
20.3.10.7.2. Product Strategy
20.3.10.7.3. Channel Strategy
20.3.11. MerzPharma
20.3.11.1. Overview
20.3.11.2. Product & Services Portfolio
20.3.11.3. Key Financials
20.3.11.4. SWOT Analysis
20.3.11.5. Key Developments
20.3.11.6. Sales Footprint
20.3.11.7. Strategy Overview
20.3.11.7.1. Marketing Strategy
20.3.11.7.2. Product Strategy
20.3.11.7.3. Channel Strategy
20.3.12. Enzon Pharmaceuticals Inc.
20.3.12.1. Overview
20.3.12.2. Product & Services Portfolio
20.3.12.3. Key Financials
20.3.12.4. SWOT Analysis
20.3.12.5. Key Developments
20.3.12.6. Sales Footprint
20.3.12.7. Strategy Overview
20.3.12.7.1. Marketing Strategy
20.3.12.7.2. Product Strategy
20.3.12.7.3. Channel Strategy
20.3.13. Glenmark,
20.3.13.1. Overview
20.3.13.2. Product & Services Portfolio
20.3.13.3. Key Financials
20.3.13.4. SWOT Analysis
20.3.13.5. Key Developments
20.3.13.6. Sales Footprint
20.3.13.7. Strategy Overview
20.3.13.7.1. Marketing Strategy
20.3.13.7.2. Product Strategy
20.3.13.7.3. Channel Strategy
20.3.14. Dr. Reddy's Laboratories
20.3.14.1. Overview
20.3.14.2. Product & Services Portfolio
20.3.14.3. Key Financials
20.3.14.4. SWOT Analysis
20.3.14.5. Key Developments
20.3.14.6. Sales Footprint
20.3.14.7. Strategy Overview
20.3.14.7.1. Marketing Strategy
20.3.14.7.2. Product Strategy
20.3.14.7.3. Channel Strategy
20.3.15. F. Hoffmann-La Roche Ltd.
20.3.15.1. Overview
20.3.15.2. Product & Services Portfolio
20.3.15.3. Key Financials
20.3.15.4. SWOT Analysis
20.3.15.5. Key Developments
20.3.15.6. Sales Footprint
20.3.15.7. Strategy Overview
20.3.15.7.1. Marketing Strategy
20.3.15.7.2. Product Strategy
20.3.15.7.3. Channel Strategy
20.3.16. Teva Pharmaceutical Industries Ltd.
20.3.16.1. Overview
20.3.16.2. Product & Services Portfolio
20.3.16.3. Key Financials
20.3.16.4. SWOT Analysis
20.3.16.5. Key Developments
20.3.16.6. Sales Footprint
20.3.16.7. Strategy Overview
20.3.16.7.1. Marketing Strategy
20.3.16.7.2. Product Strategy
20.3.16.7.3. Channel Strategy
20.3.17. Hikma Pharmaceuticals PLC
20.3.17.1. Overview
20.3.17.2. Product & Services Portfolio
20.3.17.3. Key Financials
20.3.17.4. SWOT Analysis
20.3.17.5. Key Developments
20.3.17.6. Sales Footprint
20.3.17.7. Strategy Overview
20.3.17.7.1. Marketing Strategy
20.3.17.7.2. Product Strategy
20.3.17.7.3. Channel Strategy
20.3.18. Sun Pharmaceutical Industries Ltd.
20.3.18.1. Overview
20.3.18.2. Product & Services Portfolio
20.3.18.3. Key Financials
20.3.18.4. SWOT Analysis
20.3.18.5. Key Developments
20.3.18.6. Sales Footprint
20.3.18.7. Strategy Overview
20.3.18.7.1. Marketing Strategy
20.3.18.7.2. Product Strategy
20.3.18.7.3. Channel Strategy
20.3.19. Apotex Inc.,
20.3.19.1. Overview
20.3.19.2. Product & Services Portfolio
20.3.19.3. Key Financials
20.3.19.4. SWOT Analysis
20.3.19.5. Key Developments
20.3.19.6. Sales Footprint
20.3.19.7. Strategy Overview
20.3.19.7.1. Marketing Strategy
20.3.19.7.2. Product Strategy
20.3.19.7.3. Channel Strategy
20.3.20. Zydus Cadila,
20.3.20.1. Overview
20.3.20.2. Product & Services Portfolio
20.3.20.3. Key Financials
20.3.20.4. SWOT Analysis
20.3.20.5. Key Developments
20.3.20.6. Sales Footprint
20.3.20.7. Strategy Overview
20.3.20.7.1. Marketing Strategy
20.3.20.7.2. Product Strategy
20.3.20.7.3. Channel Strategy
20.3.21. Aurobindo Pharma,
20.3.21.1. Overview
20.3.21.2. Product & Services Portfolio
20.3.21.3. Key Financials
20.3.21.4. SWOT Analysis
20.3.21.5. Key Developments
20.3.21.6. Sales Footprint
20.3.21.7. Strategy Overview
20.3.21.7.1. Marketing Strategy
20.3.21.7.2. Product Strategy
20.3.21.7.3. Channel Strategy
20.3.22. Cipla Inc.
20.3.22.1. Overview
20.3.22.2. Product & Services Portfolio
20.3.22.3. Key Financials
20.3.22.4. SWOT Analysis
20.3.22.5. Key Developments
20.3.22.6. Sales Footprint
20.3.22.7. Strategy Overview
20.3.22.7.1. Marketing Strategy
20.3.22.7.2. Product Strategy
20.3.22.7.3. Channel Strategy
20.3.23. Pfizer Inc.,
20.3.23.1. Overview
20.3.23.2. Product & Services Portfolio
20.3.23.3. Key Financials
20.3.23.4. SWOT Analysis
20.3.23.5. Key Developments
20.3.23.6. Sales Footprint
20.3.23.7. Strategy Overview
20.3.23.7.1. Marketing Strategy
20.3.23.7.2. Product Strategy
20.3.23.7.3. Channel Strategy
20.3.24. Torrent Pharmaceuticals Ltd.
20.3.24.1. Overview
20.3.24.2. Product & Services Portfolio
20.3.24.3. Key Financials
20.3.24.4. SWOT Analysis
20.3.24.5. Key Developments
20.3.24.6. Sales Footprint
20.3.24.7. Strategy Overview
20.3.24.7.1. Marketing Strategy
20.3.24.7.2. Product Strategy
20.3.24.7.3. Channel Strategy
20.3.25. Bayer AG
20.3.25.1. Overview
20.3.25.2. Product & Services Portfolio
20.3.25.3. Key Financials
20.3.25.4. SWOT Analysis
20.3.25.5. Key Developments
20.3.25.6. Sales Footprint
20.3.25.7. Strategy Overview
20.3.25.7.1. Marketing Strategy
20.3.25.7.2. Product Strategy
20.3.25.7.3. Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Anti-fungal Therapy Market
